Q1 2017 13F Holders as of 3/31/2017
-
Type / Class
-
Equity / American Depositary Shares, each representing 1 Ordinary Shares
-
Shares outstanding
-
100M
-
Number of holders
-
38
-
Total 13F shares, excl. options
-
5.7M
-
Shares change
-
+44K
-
Total reported value, excl. options
-
$137M
-
Value change
-
+$1.86M
-
Put/Call ratio
-
4.63
-
Number of buys
-
15
-
Number of sells
-
-15
-
Price
-
$24.00
Significant Holders of Cellectis S.A. - American Depositary Shares, each representing 1 Ordinary Shares (CLLS) as of Q1 2017
47 filings reported holding CLLS - Cellectis S.A. - American Depositary Shares, each representing 1 Ordinary Shares as of Q1 2017.
Cellectis S.A. - American Depositary Shares, each representing 1 Ordinary Shares (CLLS) has 38 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.7M shares
of 100M outstanding shares and own 5.68% of the company stock.
Largest 10 shareholders include FMR LLC (3.53M shares), ORBIMED ADVISORS LLC (350K shares), Tekla Capital Management LLC (310K shares), LAZARD ASSET MANAGEMENT LLC (299K shares), FRANKLIN RESOURCES INC (244K shares), SPHERA FUNDS MANAGEMENT LTD. (160K shares), Artal Group S.A. (150K shares), Abingworth LLP (100K shares), venBio Select Advisor LLC (97.1K shares), and DAFNA Capital Management LLC (76.4K shares).
This table shows the top 38 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.